<DOC>
	<DOCNO>NCT01857622</DOCNO>
	<brief_summary>To assess safety pharmacokinetics DU-176b administer non-valvular atrial fibrillation patient severe renal impairment , compare DU-176b administer non-valvular atrial fibrillation ( NVAF ) patient normal renal function mild renal impairment ( Normal/MiRI ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study DU-176b Administered Non-valvular Atrial Fibrillation With Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients NVAF SRI , patient NVAF Normal/MiRI . Patients hemodialysis patient may start hemodialysis followup assessment Patients significantly high risk bleed Patients receive treatment anticoagulant drug exclude warfarin , rivaroxaban , dabigatran Patients evidence hepatic function test abnormality</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>severe renal impairment</keyword>
</DOC>